Twist Bioscience Teams Up with Synthetic Design Lab for Novel Therapeutic Development
ByAinvest
Tuesday, Sep 2, 2025 8:04 am ET1min read
TWST--
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, commented on the collaboration, stating, "With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel engineered therapeutics. We are uniquely positioned to support Synthetic Design Lab’s development of novel antibody-drug conjugates for various cancer types" [1].
Daniel S. Chen, M.D., Ph.D., Chief Executive Officer of Synthetic Design Lab, expressed his enthusiasm for the collaboration, stating, "Collaborating with Twist, we’re able to leverage their extensive suite of high throughput services to help us advance on our mission to unlock the full potential of our proprietary approach. We believe that with our SYNTHBODY platform, we can develop a broad suite of therapeutics that are far more advanced than what is available today" [1].
Twist Bioscience will utilize its proprietary tools and platform to conduct specific research activities, supporting Synthetic Design Lab's efforts. The collaboration aims to accelerate the discovery and development of novel therapeutics, potentially offering significant advancements in cancer treatment [1].
References:
[1] https://www.stocktitan.net/news/TWST/twist-bioscience-collaborates-with-synthetic-design-6kxplpcsob7n.html
Twist Bioscience has collaborated with Synthetic Design Lab to support the development of novel antibody-drug conjugates for cancer treatment. Twist will leverage its high throughput services and expertise in antibody engineering to advance Synthetic Design Lab's mission to unlock the full potential of its SYNTHBODY platform. The collaboration aims to accelerate the discovery and development of novel therapeutics.
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, has entered into a collaboration with Synthetic Design Lab (SDL), a next-generation therapeutics company, to support the development of novel antibody-drug conjugates (ADCs) for various cancer types. The collaboration leverages Twist Bioscience's high throughput expertise in novel binder discovery services and high throughput screening capabilities to accelerate Synthetic Design Lab's mission to unlock the full potential of its SYNTHBODY platform [1].Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, commented on the collaboration, stating, "With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel engineered therapeutics. We are uniquely positioned to support Synthetic Design Lab’s development of novel antibody-drug conjugates for various cancer types" [1].
Daniel S. Chen, M.D., Ph.D., Chief Executive Officer of Synthetic Design Lab, expressed his enthusiasm for the collaboration, stating, "Collaborating with Twist, we’re able to leverage their extensive suite of high throughput services to help us advance on our mission to unlock the full potential of our proprietary approach. We believe that with our SYNTHBODY platform, we can develop a broad suite of therapeutics that are far more advanced than what is available today" [1].
Twist Bioscience will utilize its proprietary tools and platform to conduct specific research activities, supporting Synthetic Design Lab's efforts. The collaboration aims to accelerate the discovery and development of novel therapeutics, potentially offering significant advancements in cancer treatment [1].
References:
[1] https://www.stocktitan.net/news/TWST/twist-bioscience-collaborates-with-synthetic-design-6kxplpcsob7n.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet